1. P347 Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases. (27th May 2021) Authors: Attauabi, M; Höglund, C; Fassov, J; Pedersen, K B; Bansholm Hansen, H; Wildt, S; Dam Jensen, M; Neumann, A; Lind, C; Albæk Jacobsen, H; Popa, A M; Kjeldsen, J; Pedersen, N; Molazahi, A; Haderselv, K; Aalykke, C; Knudsen, T; Cebula, W; Munkholm, P; Bendtsen, F Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S369 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P602 Vedolizumab subcutaneous influencing disease course in Constant-care app solution. (27th May 2021) Authors: Nørgaard, J; Malte, R; Charlotte, P L; Mette, B; Eva, F; Petra, W; Dorit, A; Lotte, S; Johan, B; Pia, M Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S547 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗